Industry Outlook

Dravet syndrome treatment accounted for a market value of US$ 288.2 Mn in 2021 and projected to grow at a CAGR of 11.7% during the forecast period from 2023 to 2030. The current treatment options available for Dravet syndrome target specifically the symptomatic relief associated with epileptic seizures. However, recent drug approvals for Dravet syndrome treatment has increased the overall market size and attracted attention of major pharmaceutical companies. In June 2020, Epidiolex (Cannabidiol) from GW Pharmaceuticals approved by USFDA specifically for Dravet syndrome. Epidiolex was followed by Fintepla (Earlier ZX008) owned by Zogenix is under approval process in the U.S. & Europe, this announcement soared shares of Zogenix by 20.5% in March 2021. Thus, overall target specific drugs are entering in the Dravet syndrome treatment horizon due to which its market growth expected to spurt from 2023 to 2030.

"Stiripentol and cannabidiol will assist the significant growth of Dravet syndrome treatment market throughout the forecast period"

In August 2020, the U.S. Food and Drug Administration (FDA) had approved stiripentol brand named as Diacomit to treat seizures associated with Dravet syndrome. Stiripentol’s market share is growing at significant rate post 2020 due to higher efficiency, safety and prolonged relief from seizures. In addition to that, cannabidiol brand named as Epidiolex manufactured by GW Research Ltd. approved in June 2020. Cannabidol is first FDA-approved drug that contains a purified drug substance derived from marijuana. Thus, overall environment of Dravet syndrome treatment market is growing significantly due to strong drug pipeline and recently approved drugs.

"North America dominated the overall global market especially due to recent drug approvals and developed diagnostic technology"

In 2021, North America dominated the market and expected to maintain its dominance throughout the forecast period due to key market drivers such as rising awareness related to neurological disorders, increasing demand for target-specific drugs to treat Dravet syndrome, and high accessibility & adaptability for recently launched drugs. During the forecast period from 2021 to 2029, Asia Pacific expected to grow significantly throughout the forecast period due to increasing awareness related to Dravet syndrome coupled with developing diagnostic technologies in neurological disease area.

The key market players involved in the Dravet syndrome treatment industry studied based on financial data, product portfolio, current press releases, and key market strategies. This report also covers attractive investment proposition analyzed based on exclusive geographical PESTEL analysis. Major companies included in the report are GW Pharmaceuticals Plc., Ovid Therapeutics, PTC Therapeutics, Inc., Epygenix Therapeutics, Inc., Zogenix, Inc., Takeda Pharmaceutical Company Ltd., Biocodex S.A., OPKO Health Inc., and Biscayne Neurotherapeutics, Inc. among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Dravet Syndrome Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Dravet Syndrome Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Dravet Syndrome Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Dravet Syndrome Treatment market?
• Which is the largest regional market for Dravet Syndrome Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Dravet Syndrome Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Dravet Syndrome Treatment market worldwide?